Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Status and phase: Terminated; Phase 1

Conditions: Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Stage IV Non-small Cell Lung Cancer; Recurrent Melanoma; Recurrent Ovarian Epithelial Cancer; Previously Treated Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Recurrent Non-small Cell Lung Cancer; Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Recurrent Adult Acute Myeloid Leukemia; Stage IV Melanoma

Treatments: Biological: ipilimumab

Study type: Interventional

Funder types: NIH

Identifiers

NCT00039091

CDR0000069349 (Registry Identifier)

NCI-2012-03144

R21CA105776 (U.S. NIH Grant/Contract)

01-228

Details and patient eligibility

About

This phase I trial is studying the side effects of monoclonal antibody therapy in treating patients with ovarian epithelial cancer, melanoma, acute myeloid leukemia, myelodysplastic syndrome, or non-small cell lung cancer. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells

Full description

PRIMARY OBJECTIVES:

I. To determine the safety of MDX-CTLA-4 in patients previously and not previously vaccinated with GM-CSF-based vaccines using lethally irradiated, autologous melanoma, ovarian cancer, acute myelogenous leukemia/myelodysplasia or lung cancer cells.

II. To identify preliminary evidence of biologic activity and efficacy.

OUTLINE:

Patients receive anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody IV over 90 minutes on day 1. Courses repeat every 2 months in the absence of disease progression or unacceptable toxicity.

Patients are followed monthly until disease progression.

PROJECTED ACCRUAL: A total of 48 patients (12 per disease type; 36 previously treated with a sargramostim (GM-CSF)-expressing autologous tumor cell vaccine and 12 not previously treated with this vaccine) will be accrued for this study.

Enrollment: 26 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients previously vaccinated with GM-CSF-based vaccines using lethally irradiated, autologous melanoma, ovarian cancer, acute myelogenous leukemia/myelodysplasia, or non-small cell lung cancer cells; patients with acute myelogenous leukemia/myelodysplasia or non-small cell lung cancer who have not been vaccinated with an autologous, GM-CSF based vaccine
• >= 4 weeks since treatment (chemo-, radiation, hormone, immuno-, etc., therapy)
• Patients must have recovered from any acute toxicity associated with prior therapy
• Measurable epithelial ovarian cancer, melanoma, AML/MDS, or non-small cell lung cancer
• No standard curative treatment options
• Not require immediate palliative therapy
• Patients with epithelial ovarian cancer must have persistent or recurrent disease following primary surgery and primary chemotherapy
• Patients with melanoma must be stage IV disease
• Patients with AML/MDS, but without MDS, must be: a) in second relapse or b) first relapse with no option for bone marrow transplant or c) not a candidate for immunosuppressive chemotherapy due to age or comorbid disease
• Patients with non-small cell lung cancer must be not curable by standard surgery, chemotherapy, and/or radiation
• Life expectancy >= 12 weeks
• ECOG performance status of 0, 1 or 2
• Written informed consent
• Due to the unknown effects of MDX-CTLA-4 on the fetus or nursing infant, pregnant or nursing women should not be included; women should be either: post-menopausal for at least 1 year; surgically incapable of bearing children; or utilizing an intrauterine device, and/or spermicide and barrier, for contraception; during the study, use of oral contraception alone is not acceptable; women of childbearing potential must have a negative serum beta-HCG pregnancy test conducted during screening, and a negative urinary beta-HCG pregnancy test conducted within 24 hours prior to treatment; due to the unknown effects of MDX-CTLA-4 on the fetus, men should not father children during the study
• WBC > 1,000 cells/mm^3 (except for AML/MDS patients)
• Serum creatinine < 2 mg/dL
• Platelets > 75,000 cells/mm^3 (except for AML/MDS patients)
• AST and ALT < 2 x UNL
• Total bilirubin < 2 x UNL

Exclusion criteria

• Active infection
• Autoimmune disease requiring immunosuppressive treatment
• Any underlying medical condition which, in the principal investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of adverse events
• Any concurrent medical condition requiring the use of systemic steroids (use of inhaled or topical steroids is acceptable)
• CNS metastases, unless previously treated and stable for at least three months
• Patients who have received prior treatment with MDX-CTLA-4

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

26 participants in 1 patient group

Treatment (ipilimumab)

Experimental group

Description:

Patients receive anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody IV over 90 minutes on day 1. Courses repeat every 2 months in the absence of disease progression or unacceptable toxicity.

Treatment:

Biological: ipilimumab